Shenzhen Hepalink Commits $22M To TPG’s Biotech Fund
November 5, 2014 — 10:30 CST
This Data Is Locked!
This area is available only to Subscribers.
Shenzhen-listed Chinese drug maker Shenzhen Hepalink Pharmaceutical Co., Ltd. has agreed to commit US$22 million to TPG Capital’s biotech fund, TPG Biotechnology Partners IV, L.P.,... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
